Cardiovascular disease in chronic renal failure: pathophysiologic aspects

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Cardiovascular complications are the primary cause of mortality in end-stage renal disease (ESRD) patients.
• This elevated risk is linked to hemodynamic overload and uremia-specific metabolic/endocrine issues.
• Cardiovascular disease (CVD) encompasses heart (e.g., left ventricular hypertrophy [LVH]) and vascular (e.g., atherosclerosis) disorders.

Purpose of the Study:

• To review the pathophysiology of cardiovascular disease (CVD) in end-stage renal disease (ESRD).
• To summarize recent findings on therapeutic approaches for CVD in ESRD.
• To highlight the impact of LVH and arterial stiffness on prognosis.

Main Methods:

• Literature review of recent works on CVD pathophysiology in ESRD.
• Analysis of factors contributing to cardiovascular risk in renal disease.
• Summary of therapeutic strategies targeting hemodynamic overload and vascular damage.

Main Results:

• Left ventricular hypertrophy (LVH) is common in ESRD, driven by pressure/volume overload, and predicts poor outcomes.
• Damage to large arteries, including calcified lesions and stiffness, significantly contributes to major cardiovascular events.
• Regression of LVH and improved arterial stiffness are associated with better prognosis and survival.

Conclusions:

• Addressing hemodynamic overload and vascular abnormalities is crucial for managing CVD in ESRD.
• Interventions targeting LVH regression and arterial stiffness improvement can enhance patient survival.
• A comprehensive approach to CVD in ESRD requires managing both cardiac and vascular pathologies.